BioVex Limited has signed an agreement with Merck & Co Inc. BioVex will supply Merck with its proprietary NeuroVEX vectors that allow highly efficient and non-toxic gene delivery to the cells and tissues of the nervous system. Merck will evaluate the vectors at laboratory sites in both the USA and the UK.
NeuroVEX can be used to establish long-term foreign gene expression in nerve cells and may be useful in the identification of new gene targets for small molecule drugs to treat diseases and disorders of the central and peripheral nervous systems.